BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 30333313)

  • 1. Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.
    Takasaka N; Seed RI; Cormier A; Bondesson AJ; Lou J; Elattma A; Ito S; Yanagisawa H; Hashimoto M; Ma R; Levine MD; Publicover J; Potts R; Jespersen JM; Campbell MG; Conrad F; Marks JD; Cheng Y; Baron JL; Nishimura SL
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy.
    Dodagatta-Marri E; Ma HY; Liang B; Li J; Meyer DS; Chen SY; Sun KH; Ren X; Zivak B; Rosenblum MD; Headley MB; Pinzas L; Reed NI; Del Cid JS; Hann BC; Yang S; Giddabasappa A; Noorbehesht K; Yang B; Dal Porto J; Tsukui T; Niessen K; Atakilit A; Akhurst RJ; Sheppard D
    Cell Rep; 2021 Jul; 36(1):109309. PubMed ID: 34233193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer cells promote CD169
    Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
    Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8.
    Stockis J; Liénart S; Colau D; Collignon A; Nishimura SL; Sheppard D; Coulie PG; Lucas S
    Proc Natl Acad Sci U S A; 2017 Nov; 114(47):E10161-E10168. PubMed ID: 29109269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A tumor-specific mechanism of T
    Seed RI; Kobayashi K; Ito S; Takasaka N; Cormier A; Jespersen JM; Publicover J; Trilok S; Combes AJ; Chew NW; Chapman J; Krummel MF; Lou J; Marks J; Cheng Y; Baron JL; Nishimura SL
    Sci Immunol; 2021 Mar; 6(57):. PubMed ID: 33771888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrin alphavbeta8-mediated activation of transforming growth factor-beta inhibits human airway epithelial proliferation in intact bronchial tissue.
    Fjellbirkeland L; Cambier S; Broaddus VC; Hill A; Brunetta P; Dolganov G; Jablons D; Nishimura SL
    Am J Pathol; 2003 Aug; 163(2):533-42. PubMed ID: 12875973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of exosomal PD-L1 in tumor progression and immunotherapy.
    Xie F; Xu M; Lu J; Mao L; Wang S
    Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
    Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
    Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.
    de Streel G; Bertrand C; Chalon N; Liénart S; Bricard O; Lecomte S; Devreux J; Gaignage M; De Boeck G; Mariën L; Van De Walle I; van der Woning B; Saunders M; de Haard H; Vermeersch E; Maes W; Deckmyn H; Coulie PG; van Baren N; Lucas S
    Nat Commun; 2020 Sep; 11(1):4545. PubMed ID: 32917858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
    Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
    J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated macrophage enhances PD-L1-mediated immune escape of bladder cancer through PKM2 dimer-STAT3 complex nuclear translocation.
    Yu Y; Liang Y; Xie F; Zhang Z; Zhang P; Zhao X; Zhang Z; Liang Z; Li D; Wang L; Chen Y; Sun L; Niu H; Wang Y
    Cancer Lett; 2024 Jul; 593():216964. PubMed ID: 38762193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.
    Lau J; Cheung J; Navarro A; Lianoglou S; Haley B; Totpal K; Sanders L; Koeppen H; Caplazi P; McBride J; Chiu H; Hong R; Grogan J; Javinal V; Yauch R; Irving B; Belvin M; Mellman I; Kim JM; Schmidt M
    Nat Commun; 2017 Feb; 8():14572. PubMed ID: 28220772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.